Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,781 total articles

Cycurion Delivers on 2026 Profitable Growth Strategy with $6 Million Win and $112 Million Backlog Powered by Innovative AI Solutions

Cycurion Delivers on 2026 Profitable Growth Strategy with $6 Million Win and $112 Million Backlog Powered by Innovative AI Solutions

Cycurion, a U.S.-based AI-driven cybersecurity and government technology solutions provider, announced a $6 million purchase order under a multi-year Master Services Agreement with a major U.S. municipality. This award adds to Cycurion's total contracted backlog of $112 million and strengthens its position in municipal technology services. The comp…

Citizens Community Bancorp, Inc. Reports First Quarter 2026 Earnings of $0.39 Per Share; Board Approves Quarterly Dividend at $0.105 per Share

Citizens Community Bancorp, Inc. Reports First Quarter 2026 Earnings of $0.39 Per Share; Board Approves Quarterly Dividend at $0.105 per Share

Citizens Community Bancorp, Inc. reported first quarter 2026 net income of $3.8 million or $0.39 per diluted share, compared to $4.3 million or $0.44 per share in Q4 2025 and $3.2 million or $0.32 in Q1 2025. Key factors included 1.3% loan growth, 2.7% deposit growth, a slight increase in net interest margin to 3.18%, and higher provisions for cred…

Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor

Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor

Solana Company (NASDAQ: HSDT) announced a registered direct offering of 3,076,922 shares of Class A common stock at $2.60 per share, generating approximately $8 million in gross proceeds. The offering was led by Mirae Asset with participation from Hashkey Capital. The company plans to use the net proceeds primarily to acquire more Solana (SOL) toke…

Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

Erasca, Inc., a clinical-stage precision oncology company, announced it will hold a conference call to discuss preliminary Phase 1 dose escalation data for its oral pan-RAS molecular glue ERAS-0015. The early data shows favorable safety, tolerability, and encouraging partial responses in patients with various RAS-mutant solid tumors, supporting its…

Greenland Energy (NASDAQ: GLND) Signs Halliburton Agreement for 2026 Jameson Land Drilling Campaign

Greenland Energy (NASDAQ: GLND) Signs Halliburton Agreement for 2026 Jameson Land Drilling Campaign

Greenland Energy Company has entered into a key agreement with Halliburton to provide integrated consulting and well drilling services for its 2026 onshore exploration campaign in the Jameson Land Basin, Greenland. This agreement complements prior contracts with Stampede Drilling and Desgagnés, forming a cohesive operational strategy for Arctic ene…

IperionX – March 2026 Quarterly Report

IperionX – March 2026 Quarterly Report

IperionX Limited reported successful ramp-up to 24/7 titanium powder production at its Virginia facility, progressing from commissioning to continuous operations. The company advanced proprietary HAMR and HSPT technologies and expanded powder metallurgy manufacturing capacity. Engagement with defense, aerospace, automotive, and industrial customers…

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Tenaya Therapeutics announced acceptance of multiple abstracts for presentation at the ASGCT Annual Meeting, including late-breaking data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy in adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The data cover safety, biopsy, and efficacy from two dose cohorts, w…

Costamare Inc. Sets the Date for Its First Quarter 2026 Results Release, Conference Call and Webcast

Costamare Inc. Sets the Date for Its First Quarter 2026 Results Release, Conference Call and Webcast

Costamare Inc., a leading owner and provider of containerships for charter, is set to release its first quarter 2026 financial results on April 29, 2026, before the market opens. Management will host a conference call and webcast to discuss the results. The company operates a fleet of 79 containerships and is publicly traded on the NYSE under ticke…

VivoPower Targets $1.9 Million Annualized EBITDA Uplift from Enrollment of Norway Data Center into Statnett Reserve Markets Demand Response Program

VivoPower Targets $1.9 Million Annualized EBITDA Uplift from Enrollment of Norway Data Center into Statnett Reserve Markets Demand Response Program

VivoPower PLC announced that its Mo i Rana data center in Northern Norway has prequalified 30 MW of capacity for participation in Statnett SF's ancillary services markets, expected to generate approximately $1.9 million in incremental annual EBITDA by fiscal year 2027. This demand response enrollment requires no incremental capital expenditure and …

Norwood Financial Corp announces First Quarter Financial Results

Norwood Financial Corp announces First Quarter Financial Results

Norwood Financial Corp announced first quarter 2026 results highlighting the successful acquisition of Presence Bancshares and completion of a core system conversion. The company reported record net interest income of $24.6 million and tangible book value per share of $22.43. Despite merger-related expenses impacting net income ($3.7 million for th…

NXP Announces Availability of Proxy Materials for the Annual General Meeting of Shareholders to Be Held on June 10, 2026

NXP Announces Availability of Proxy Materials for the Annual General Meeting of Shareholders to Be Held on June 10, 2026

NXP Semiconductors announced the availability of proxy materials for its upcoming Annual General Meeting of Shareholders to be held on June 10, 2026. The company filed its definitive proxy statement and annual report with the SEC and will distribute the notice of internet availability of proxy materials by May 20, 2026. Shareholders can also reques…

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Oncolytics Biotech announced FDA alignment on the design of a pivotal randomized controlled trial for pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal who have exhausted standard treatments. The trial aims to support both accelerated and full approval based on multiple endpoints. Previous studies show pr…

New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy

New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy

iRhythm Holdings announced new data presented at HRS 2026 showing that short-term Holter monitoring (24-48 hours) misses a significant proportion of atrial fibrillation (AF) recurrences post-ablation and clinically significant arrhythmias during pregnancy. Their Zio ambulatory ECG device, offering continuous monitoring up to 14 days, demonstrated s…

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Terns Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to TERN-701, an oral allosteric BCR::ABL1 inhibitor targeting adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. This designation recognizes TERN-701's potential to offer substantial clinical improvement i…